

molnupiravir hard capsules (Lagevrio®)

Merck Sharp & Dohme (UK) Ltd

16 April 2025 (updated 26 February 2026)

The Scottish Medicines Consortium (SMC) collaborated with the National Institute for Health and Care Excellence (NICE) and following review by the SMC Executive, SMC advises NHS boards and Area Drug and Therapeutics Committees (ADTCs) on the use of the above product in NHSScotland. The collaboration includes an update to remove sotrovimab because the company has discontinued manufacturing, supply, distribution and marketing of sotrovimab in the UK (update published February 2026). The advice is as follows:

ADVICE: following SMC collaboration with NICE on *TA1056: molnupiravir for treating COVID-19*

molnupiravir (Lagevrio®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.

SMC restriction: as an option for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, only if:

- they have 1 or more risk factors for progression to severe COVID-19 (as defined in [section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19](#)) and
- nirmatrelvir plus ritonavir is contraindicated or unsuitable.

Full details of the assessment and recommendations can be found at [Overview | Molnupiravir for treating COVID-19 | Guidance | NICE](#).

A budget impact template is provided in confidence to NHS boards to enable them to estimate the predicted budget for medicines accepted for restricted use.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at following collaboration with NICE. It is provided to inform the considerations of Area Drug and Therapeutics

Committees and NHS boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair

Scottish Medicines Consortium